(DNLI) – Hot FDA News
-
Denali Therapeutics (DNLI) Declines 15% Following Clinical Hold on DNL919
-
Denali Therapeutics (DNLI) Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome
Back to DNLI Stock Lookup